Former Tesla Foundation Vice Chairman Joins StHealth BDC.

St Health Capital Investment Corporation is delighted to announce Dr. Robert GW Brown FAPS, FIEE, FInstP, MAE as a key new member to our board...

Hercules BDC (HTGC) $13, to Present at FB Riley.

Hercules Capital to Discuss 2019 Growth Opportunities at the B. Riley FBR Institutional Investor Conference PALO ALTO, Calif.--(BUSINESS...

Innovus (INNV) in Silicon Review Interview.

POISED FOR INNOVATION. The Silicon Review is the world’s most trusted online and print community for business &...
internet stock review

Innovus (INNV) Conference Call Transcript.

Q1 2019 Results, 5/15/19.  Innovus Pharmaceuticals, Inc. (OTCQB:INNV) Q1 2019 Earnings Conference Call May 15, 2019 4:15 PM...
biotech stock review, fluticare

Innovus (INNV): Twenty-Eight Drugs in Five Years. (San Diego Reader)

(Originally published 4/25/2018) “I am very steady. I like to work slowly, but surely, to get to my goal.”...
biotech stock review, innovus

Adding Innovus Pharma (INNV) $2.50 to Watch List.

Fast Growing eCommerce and Direct to Consumer Pharma Company Announces 1st Foray into CBD and 2nd Major Off-Patent Blockbuster Drug to its...
candida auris, citius pharma, biotech stock review

Citius Pharma’s (CTXR) Mino-Lok® Highly Efficacious in Rapidly Eradicating Candida auris.

CRANFORD, N.J., May 13, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug...
Regoxidine, biotech stock review

Rogaine® Competitor Regoxidine™ Expected to Launch Second Half, 2019.

Innovus Pharma (INNV) Announces a Second Partnered United States OTC ANDA for Minoxidil 5% Foam for Men and Women.

Lift Off! Mustang Bio (MBIO) $9.31 Jumps 4-Fold.

‘Bubble Boy’ Biotech Soars 250 Percent After Cure Announcement (Bloomberg). (Bloomberg) -- Shares of the tiny biotechnology company...

Latest article

COVID-19 Immunity From mRNA Booster Does Not Last Very Long.

Study finds that the median length for the antibody half-life immune response was 63 days for the primary series, and increased to...

We’re in Tampa for the Kentucky Derby.

GeoVax (GOVX), Sees a Little Volume. Normally, we get a little nervous when one of the companies we...

Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.

DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...